Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131481) titled 'Study on the efficacy and safety of Orelabrutinib Combined with Rituximab in the Treatment of Ralapaed and refractory warm Autoimmune Hemolytic Anemia' on Sept. 2.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine
Condition:
Relapsed and refractory warm antibody autoimmune hemolytic anemia
Intervention:
The group of Orelabrutinib plus rituximab:Rituximab: 100 mg per day, on days 1, 8, 15, and 22, for a total of 4 times
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-02
T...